CATX

Perspective Therapeutics Inc. (CATX) | Rumor.io

Perspective Therapeutics

CATX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,299

Bullish sentiment (50-day avg)70%

Price to earnings ratio-1.81

Market capitalization285.4M

Earnings per share-1.33

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-103.1M

Social

What share of all stock conversation is about CATX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 24

Lantheus Holdings has been aggressively selling CATX stock, with 2.3 million shares sold between September 18-22 at an average price of $2.93.
The sale is believed to be for "housekeeping" purposes, as the company is being acquired by Curium and the sale is seen as irrelevant to the company's future prospects.
The sale has led to a significant drop in the market capitalization of CATX, with some speculating that the stock could go to zero.

Generated by AI

Sentiment

Of the messages about CATX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	45% -41	65.5% -21.68	82.41% +5.22
Bearish	0% 0	55% +41	34.5% +21.68	17.59% -5.22

Bullish· Feb 19

Institutional buying is occurring in $CATX, supporting the stock's upward trend.
Multiple upgrades and buy recommendations, including one from Piper Sandler with a price target of $16, are contributing to the stock's bullish sentiment.
The stock has seen significant short interest, with over 9 million shares short, which could lead to a "REAL bad" situation for shorts once buyers come in.

Bearish· Sep 23

The stock has fallen for 6 straight months, and the author is waiting for clinical updates expected by the end of October, which could lead to a 6% drop.
The stock has a high short interest, and the author is concerned that a 7% drop could occur if the shorts are covered.
The stock has a high percentage of shares owned by promoters, and the author believes this is a sign of a manipulated market.

Generated by AI

Topics

Of the messages about CATX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80%	36.1%
Analysts	—	0%	16%	19.14%
Technical Analysis	—	0%	4%	36.2%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.71%
Macro	—	0%	0%	7.85%

Announcements· Feb 2

Perspective Therapeutics, Inc. (CATX) has raised $175 million through an underwritten offering of 39,576,088 shares of its common stock and pre-funded warrants.
The capital raise is expected to fuel the company's pipeline in targeted radiopharmaceuticals, positioning it for significant growth and accelerating its approval timeline.
Analyst firms HC Wainwright and Wedbush have reaffirmed bullish ratings on CATX, with price targets ranging from $11 to $12, likely fueling investor optimism and contributing to the stock's surge.

Technical Analysis· Feb 2

$CATX has been stair stepping upward and is showing potential for further growth, with a near-perfect pennant formation and a cup and handle setup.
The stock's RSI was super hot, indicating a good pullback, and the MACD is about to roll over, with strong support built at $5.
$CATX has broken key resistance at $4.25 on massive volume, confirming powerful technical momentum, with a next target of $6.99.

Generated by AI

Community

Of the messages about CATX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	39.13%	77.63%	56.98%	58.56%
Newcomers	60.87%	22.37%	43.02%	41.44%

Regulars· Sep 23

The upcoming presentation of updated VMT-α-NET data on October 19 is expected to provide key safety and efficacy results in advanced SSTR2+ neuroendocrine tumors, which could have a significant impact on the company's valuation.
Perspective Therapeutics, Inc. has raised approximately $450 million in funding, which, based on the 2.4x value premium of Isotope Technologies Munich SE, could translate to a market capitalization of around $1.1 billion, or approximately $11 per share.
Despite the recent downtrend, the stock has seen significant buying activity, with one participant purchasing 10,000 shares at $2.53 and another adding an additional 10,000 shares at a similar price, indicating potential support at this level.

Newcomers· Feb 2

Newcomers are focusing on the recent price surge of $CATX, with some attributing it to a large underwritten equity offering that priced today, expected to raise $175 million.
The company's new price target has been raised to $12 by HC Wainwright & Co. and maintained with a $11.00/Share by Wedbush, indicating increased optimism about its prospects.
The stock has broken key resistance at $4.25 on massive volume, with some traders seeing a clean v-reversal setup and potential for the rebound to accelerate.

Generated by AI

News

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com

16d agoYahoo Finance

Also Discussed

Investors talking about CATX also mention

#	Name	Attention
1	Intellicheck Inc.IDN	0%new
2	Abeona Therapeutics Inc.ABEO	0%+0
3	Proficient Auto Logistics, Inc.PAL	0%0
4	Ballard Power Systems Inc.BLDP	0%0
5	Green Brick Partners, Inc.GRBK	0%0
6	IRSA Inversiones y Representaciones S.A. ADRIRS	0%new
7	NLTX - Neoleukin Therapeutics, Inc.	——
8	PNT - POINT Biopharma Global Inc.	——
9	Opus Genetics Inc.OCUP	0%0
10	RYZB - RayzeBio, Inc. Common Stock	——

Perspective Therapeutics Inc.

Healthcare
Medical Devices

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.

Website

Location

2401 Elliott Avenue

Seattle, WA, 98121

United States

Social

What share of all stock conversation is about CATX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 24

Lantheus Holdings has been aggressively selling CATX stock, with 2.3 million shares sold between September 18-22 at an average price of $2.93.
The sale is believed to be for "housekeeping" purposes, as the company is being acquired by Curium and the sale is seen as irrelevant to the company's future prospects.
The sale has led to a significant drop in the market capitalization of CATX, with some speculating that the stock could go to zero.

Generated by AI

Sentiment

Of the messages about CATX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	45% -41	65.5% -21.68	82.41% +5.22
Bearish	0% 0	55% +41	34.5% +21.68	17.59% -5.22

Bullish· Feb 19

Institutional buying is occurring in $CATX, supporting the stock's upward trend.
Multiple upgrades and buy recommendations, including one from Piper Sandler with a price target of $16, are contributing to the stock's bullish sentiment.
The stock has seen significant short interest, with over 9 million shares short, which could lead to a "REAL bad" situation for shorts once buyers come in.

Bearish· Sep 23

The stock has fallen for 6 straight months, and the author is waiting for clinical updates expected by the end of October, which could lead to a 6% drop.
The stock has a high short interest, and the author is concerned that a 7% drop could occur if the shorts are covered.
The stock has a high percentage of shares owned by promoters, and the author believes this is a sign of a manipulated market.

Generated by AI

Topics

Of the messages about CATX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80%	36.1%
Analysts	—	0%	16%	19.14%
Technical Analysis	—	0%	4%	36.2%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.71%
Macro	—	0%	0%	7.85%

Announcements· Feb 2

Perspective Therapeutics, Inc. (CATX) has raised $175 million through an underwritten offering of 39,576,088 shares of its common stock and pre-funded warrants.
The capital raise is expected to fuel the company's pipeline in targeted radiopharmaceuticals, positioning it for significant growth and accelerating its approval timeline.
Analyst firms HC Wainwright and Wedbush have reaffirmed bullish ratings on CATX, with price targets ranging from $11 to $12, likely fueling investor optimism and contributing to the stock's surge.

Technical Analysis· Feb 2

$CATX has been stair stepping upward and is showing potential for further growth, with a near-perfect pennant formation and a cup and handle setup.
The stock's RSI was super hot, indicating a good pullback, and the MACD is about to roll over, with strong support built at $5.
$CATX has broken key resistance at $4.25 on massive volume, confirming powerful technical momentum, with a next target of $6.99.

Generated by AI

Community

Of the messages about CATX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	39.13%	77.63%	56.98%	58.56%
Newcomers	60.87%	22.37%	43.02%	41.44%

Regulars· Sep 23

The upcoming presentation of updated VMT-α-NET data on October 19 is expected to provide key safety and efficacy results in advanced SSTR2+ neuroendocrine tumors, which could have a significant impact on the company's valuation.
Perspective Therapeutics, Inc. has raised approximately $450 million in funding, which, based on the 2.4x value premium of Isotope Technologies Munich SE, could translate to a market capitalization of around $1.1 billion, or approximately $11 per share.
Despite the recent downtrend, the stock has seen significant buying activity, with one participant purchasing 10,000 shares at $2.53 and another adding an additional 10,000 shares at a similar price, indicating potential support at this level.

Newcomers· Feb 2

Newcomers are focusing on the recent price surge of $CATX, with some attributing it to a large underwritten equity offering that priced today, expected to raise $175 million.
The company's new price target has been raised to $12 by HC Wainwright & Co. and maintained with a $11.00/Share by Wedbush, indicating increased optimism about its prospects.
The stock has broken key resistance at $4.25 on massive volume, with some traders seeing a clean v-reversal setup and potential for the rebound to accelerate.

Generated by AI

Perspective Therapeutics

Social

Sep 24

Bullish· Feb 19

Bearish· Sep 23

Announcements· Feb 2

Technical Analysis· Feb 2

Regulars· Sep 23

Newcomers· Feb 2

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics stock with outperform rating

William Blair Initiates Perspective Therapeutics With Outperform Rating

Perspective Therapeutics at Morgan Stanley conference: alpha-drug push

Perspective Therapeutics partners with Merck on cancer trial

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

Also Discussed

Perspective Therapeutics Inc.

Company Information

Location

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics stock with outperform rating

William Blair Initiates Perspective Therapeutics With Outperform Rating

Perspective Therapeutics at Morgan Stanley conference: alpha-drug push

Perspective Therapeutics partners with Merck on cancer trial

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

Also Discussed

Social

Sep 24

Bullish· Feb 19

Bearish· Sep 23

Announcements· Feb 2

Technical Analysis· Feb 2

Regulars· Sep 23

Newcomers· Feb 2